palopegteriparatide

Home
Ligands
palopegteriparatide

GtoPdb Ligand ID: 13484

Synonyms: mPEG-PTH (1-34) | TransCon PTH | Yorvipath®

palopegteriparatide is an approved drug (EMA (2023), FDA (2024))

Comment: Palopegteriparatide is a synthetic parathyroid hormone mimetic prodrug. Structurally it is an N-terminally PEGylated fragment of amino acids 1-34 of the mature human peptide (84 aa) [1]. Palopegteriparatide is inactive at the PTH receptor until the peptide-PEG linker is cleaved, releasing the active PTH(1-34) peptide.

Summary
Biological activity
Clinical data
References
Structure
Similar ligands

References
1. Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M et al.. (2019) Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism. J Bone Miner Res, 34 (11): 2075-2086. [PMID:31291476]

References

1. Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M et al.. (2019)
Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
J Bone Miner Res, 34 (11): 2075-2086. [PMID:31291476]